FDA grants approval for Simplera Sync sensor compatibility with MiniMed 780G insulin pump
Medtronic, a leading medical technology company, has taken a significant step forward in diabetes care with the introduction of the Simplera Sync sensor for its MiniMed 780G system. This advanced insulin delivery system already features Meal Detection technology, and the FDA's recent approval for the Simplera Sync sensor marks a new era of convenience and ease for diabetes management.
The Simplera Sync sensor stands out for its user-friendly design. It is a disposable, all-in-one sensor that requires no fingersticks, overtape, or additional accessories for calibration. Its compact, all-in-one applicator is designed for a quick, two-step, one-handed insertion process, making sensor placement a breeze.
The sensor integrates seamlessly with the MiniMed 780G system, offering real-time continuous glucose monitoring. This integration allows the system's adaptive algorithm to automatically adjust glucose levels every 5 minutes, 24/7, ensuring optimal insulin delivery via SmartGuard technology.
The software updates accompanying the Simplera Sync sensor maintain personalized settings and enhanced algorithm memory without the need to switch pumps. Updates are managed via the MiniMed Mobile app, making system management more convenient. The sensor is suitable for persons aged 2 and older, as well as caregivers assisting children with diabetes management.
With the Simplera Sync sensor, users can experience 96% fewer injections compared to multiple daily injections. The limited launch of the sensor will begin in the U.S. in the fall of 2025.
The MiniMed 780G system's Meal Detection technology detects rising sugar levels and delivers more insulin as needed. Real-world data shows global users consistently achieve time in range above international targets of 70% when using optimal settings with the MiniMed 780G system. The system works with the world's only infusion set that lasts up to 7 days, requiring users to change their infusion set once per week.
Medtronic's commitment to innovation in diabetes care is evident in the Simplera Sync sensor. Que Dallara, EVP and president of Medtronic Diabetes, stated, "We are committed to driving innovation to make life easier for those living with diabetes." This commitment is further demonstrated by Medtronic's recent FDA approval for the world's first adaptive deep brain stimulation system for people with Parkinson's.
The MiniMed 780G system uses a "treat to target" approach and flexible glucose targets as low as 100 mg/dL. As the name suggests, this approach allows users to set specific glucose targets and adjust insulin delivery accordingly.
In conclusion, the Simplera Sync sensor offers several key features and benefits aimed at improving ease of use and diabetes management. By combining accurate, continuous glucose monitoring with simplified sensor handling and integration into an advanced insulin pump system, the MiniMed 780G system and Simplera Sync sensor contribute to a streamlined diabetes management experience.
References: 1. Medtronic Press Release 2. Medtronic Diabetes 3. Diabetes Care 4. Journal of Diabetes Science and Technology
The Simplera Sync sensor, approved by the FDA, is a significant innovation in digital health, revolutionizing diabetes management within the realm of health-and-wellness. Integrated with Medtronic's MiniMed 780G system, it offers real-time glucose monitoring and utilizes science to adjust insulin delivery effectively, enabling persons with diabetes to achieve targets efficiently.
